KRAS and non-small cell lung carcinoma: Regardless of treatment with ICIs alone or in combination with chemoimmunotherapy, comutation of KRAS and STK11 or KEAP1 was associated with a worse objective response rate and OS, and KEAP1 mutation among KRAS-wild-type NSCLC patients was correlated with inferior OS after chemoimmunotherapy [25, 29].